ABSTRACT
Since the final sample of 44,642 statin users includes persons identified as having or not having evidence of CHD, it is natural to consider whether or not each distinct sub-population reacts differently to copayment differentiation among statins. Patients without evidence of CHD (primary prevention therapy) are likely to be in better health, in general, than their counterparts. As a result, it is possible that these patients are less influenced by copayment differences among statins since the five drugs in the class are near perfect substitutes for persons in fair health.
